Basic Study
Copyright ©The Author(s) 2020.
World J Psychiatr. Aug 19, 2020; 10(8): 175-186
Published online Aug 19, 2020. doi: 10.5498/wjp.v10.i8.175
Table 1 Demographics and episodic data of the study sample
HVs, n = 18Patients, n = 22
Age in yr18.9 ± 1.217.1 ± 2.3
Gender, male/female4/144/18
BMI in kg/m223.2 ± 2.123.1 ± 2.1
Education in yr12.9 ± 1.211.5 ± 2.6
Family history, yes/no3/158/14
First episodeN/A8
Recurrent episodeN/A14
Table 2 Clinical psychiatric scores and serum chemokine levels in adolescents with major depressive disorder in 8 wk of selective serotonin reuptake inhibitor treatment
Chemokine serum levels, pg/mLHVs
Adolescents with MDD
Post hoc statistical analysis
n = 180 wk, n = 224 wk, n = 228 wk, n = 220 wk vs HVs4 wk vs 0 wk8 wk vs 0 wk
MCP-1 or CCL248.1 ± 3.7107.7 ± 31.089.8 ± 19.9102.9 ± 14.0dP < 0.0001aP < 0.05NS
MIP-1α or CCL35.4 ± 1.07.3 ± 1.46.7 ± 1.47.4 ± 1.0dP < 0.0001NSNS
MIP-1β or CCL4204.7 ± 42.2324.0 ± 61.5311.8 ± 48.1294.8 ± 34.8dP < 0.0001NSNS
IL-8 or CXCL850.2 ± 6.879.2 ± 18.066.9 ± 13.273.3 ± 9.1dP < 0.0001NSNS
IP-10 or CXCL101890.0 ± 52.72309.0 ± 545.12224.0 ± 578.52710.0 ± 220.1aP < 0.05NSaP < 0.05
Eotaxin or CCL11255.4 ± 50.4319.8 ± 65.5277.2 ± 51.8328.6 ± 50.7bP < 0.01NSNS
Clinical psychiatric scale
HDRSN/A19.4 ± 4.79.1 ± 4.726.0 ± 2.4N/AdP < 0.0001dP < 0.0001